AMENDMENTS TO THE CLAIMS:

1. (currently amended) An oral dosage form with delayed release of active ingredient and high mechanical stability, comprising
   a) one or more active ingredients
   b) from 20 to 80%, based on the total weight of the dosage form, of a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone
   c) water soluble polymers or low or high molecular weight lipophilic additives
   d) and other conventional excipients,
   wherein the ratio of polyvinyl acetate to polyvinylpyrrolidone is from 6:4 to 9:1 and said formulation facilitates said delayed release.

2. (canceled)

3. (previously presented) An oral dosage form a claimed in claim 1, wherein a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone in the ratio 8:2 is employed.

4. (previously presented) A oral dosage from as claimed in claim 1, which is a tablet, extrudate, pellet or granulate.

5. (previously presented) An oral dosage form as claimed in claim 1, wherein a water-soluble or water-insoluble release-delaying coating is applied to the oral dosage form.

6. (previously presented) An oral dosage form as claimed in claim 1, wherein the water-soluble or lipophilic polymers are selected from the group consisting of: polyvinyl alcohols, polyethylene glycols, polyoxyethylene/polyoxypropylene block copolymers, polyvinylpyrrolidones and derivatives, and vinyl acetate/vinylpyrrolidone copolymers.

7. (previously presented) An oral dosage form as claimed in claim 1, wherein the water-soluble swelling polymers are selected from the group consisting of: alginates, pectins, galactomannans, carrageenans, dextran, curdlan, pullulan, gellan, chitin, gelatin,

xanthans, hemicelluloses, cellulose derivatives and starch and salts thereof.

8. (previously presented) An oral dosage form as claimed in claim 1, wherein the lipophilic additives are selected from the group consisting of: cellulose derivatives, acrylic ester/methacrylic ester copolymers, fatty alcohols, fatty acids, fatty acid esters and fatty alcohol esters, glycerides, waxes, and lecithin.

9. (previously presented) An oral dosage form as claimed in claim 1, which is produced by direct compression, extrusion, melt extrusion, pelleting, compaction, wet granulation.

10. (previously presented) An oral dosage form as claimed in claim 1, wherein binder, extenders/fillers, disintegrants, lubricants, flow regulators, dyes, stabilizers such as antioxidants, wetting agents, preservatives, release agents, flavorings and sweeteners are employed as conventional excipients.

11. (previously presented) An oral dosage as claimed in claim 1, wherein the formulated mixture of polyvinyl acetate and polyvinylpyrrolidone is present in a proportion of from greater than 20% to less than or equal to 80% based on the total weight of the dosage form.

12. (previously presented) An oral dosage form as claimed in claim 1, wherein the water-soluble polymers and/or the lipophilic additives are present in a proportion of from 1 to 40% based on the total weight of the dosage form.

13. (previously presented) An oral dosage form as claimed in claim 1, wherein hydroxypropylmethylcellulose are employed as water-soluble polymers.

14. (previously presented) An oral dosage form as claimed in claim 1, wherein in polyvinylpyrrolidones or vinyl acetate/vinylpyrrolidone copolymers are employed was water-soluble polymers.

15. (previously presented) An oral dosage form as claimed in claim 1, which is a press-

coated tablet whose core is rich in active ingredient.

16. (previously presented) An oral dosage form as claimed in claim 1, which comprises as active ingredients food supplements or additives, vitamins, minerals or trace elements or active pharmaceutical ingredients.

17. (previously presented) An oral dosage as claimed in claim 1, which comprised active pharmaceutical ingredients as active ingredients.

18. (previously presented) The dosage form as claimed in claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of benzodiazepines, antihypertensives, vitamins, cytostatics, anesthetics, neuroleptics, antidepressants, antibiotics, antimycotics, fungicides, chemotherapeutics, urologicals, platelet aggregation inhibitors, sulfonamides, spasmolytics, hormones, immunoglobulins, sera, thyroid therapeutics, psychopharmaceuticals, antiparkinson agents and other antihyperkinetics, ophthalmologicals, neuropathy products, calcium metabolism regulators, muscle relaxants, lipid–lowering agents, liver therapeutics, coronary agents, cardiac agents, immunotherapeutics, regulatory peptides and their inhibitors, hypnotics, sedatives, gynecologicals, antigout agents, fibrinolytics, enzyme products and transport proteins, enzyme inhibitors, emetics, perfusion promoters, diuretics, diagnostics, corticoids, cholinergics, biliary therapeutics, antiasthmatics, bronchospasmolytics, beta–receptor blockers, calcium channel blockers, ACE inhibitors, arteriosclerosis remedies, antiinflammatory agents, anticoagulants, antihypotensives, antihypoglycemics, antifibrinolytics, antiepileptics, antiemetics, antidotes, antidiabetics, antiarrhythmics, antianemics, antiallergics, anthelmintics, analgesics, analeptics, aldosterone antagonists, and weight–reducing agents.

19. (previously presented) A drug for delayed release of active ingredients, which is an oral dosage form as claimed in claim 1.

20. (canceled)

21. (previously presented) Food supplements or additives, or vitamins, minerals or trace elements comprising the oral dosage form as claimed in claim 1 for delayed release of active ingredients.

22. (previously presented) An oral dosage form as claimed in claim 6 wherein the water-soluble or lipophilic polymers are selected from the group consisting of polyethylene glycols, polyvinylpyrrolidones, vinyl acetate/vinylpyrrolidone copolymers or maltodextrins, and salts thereof.

23. (previously presented) The oral dosage form as claimed in claim 7, wherein the cellulose derivatives are selected from the group consisting of methylcellulose, methylhydroxyethylcellulose, carboxymethylcellulose and wherein the starch derivatives are selected from the group consisting of carboxymethyl starch, degraded starch, polyacrylic acid, polymethacrylic acid, acrylic acid/methacrylic acid copolymers.

24. (previously presented) The oral dosage form as claimed in claim 8, wherein the lipophilic additives are selected from the group consisting of cellulose derivatives which are ethylcellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate succinate, hydroxy propylmethylcellulose acetate phthalate, or hydroxypropylmethylcellulose acetate succinate, acrylic ester/ethacrylic ester copolymers which are methyl methacrylate/ethyl acrylate copolymers, ammoniomethacrylate copolymer type A and type B, methacrylic acid/acrylic ester copolymers or methacrylic acid/ethyl acrylate copolymers, fatty alcohols which are stearyl alcohols, fatty acids which are stearic acid, fatty acid esters and fatty alcohol esters, glycerides, waxes and lecithin.

25. (new) A method for making an oral dosage form with delayed release of active ingredient and high mechanical stability by processing an oral dosage form with delayed release of active ingredient and high mechanical stability, comprising combining

a) one or more active ingredients

b) from 20 to 80%, based on the total weight of the dosage form, of a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone

c) water soluble polymers or low or high molecular weight lipophilic additives

d) and other conventional excipients,

wherein the ratio of polyvinyl acetate to polyvinylpyrrolidone is from 6:4 to 9:1 and said formulation facilitates said delayed release.

26. (new) The method for making an oral dosage form with delayed release of active ingredient and high mechanical stability by proeessing an oral dosage form with delayed release of active ingredient and high mechanical stability of claim 25 further comprising a step selected from the group consisting of melt extrusion, film coating and press coating.